MedTrace Logo

Clozapine and Haematologic Malignancies: Observational and Retrospective Study Using the WHO Pharmacovigilance Database

NCT04074213 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000000

Last updated 2019-08-30

No results posted yet for this study

Summary

Clozapine may lead to various adverse reactions, including neutropenia and agranulocytosis. This study investigates reports of lymphoma and leukaemias for clozapine in the World Health Organization's (WHO) global database of individual safety case reports (VigiBase).

Conditions

Interventions

DRUG

Clozapine

Clozapine treatment

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Principal Investigators

  • Basile Chrétien, PharmD, MSc · University Hospital, Caen

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2024-03-01
Completion
2024-08-01
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04074213 on ClinicalTrials.gov